Regulatory Focus™ > News Articles > NIH, Eli Lilly Creating Public Drug Database

NIH, Eli Lilly Creating Public Drug Database

Posted 13 March 2012 | By Alexander Gaffney, RAC 

The US National Institutes of Health (NIH) and Eli Lilly and Company are working together to create a publicly available database of thousands of approved and investigational medicines and molecules.

The collaboration will see NIH's new National Center for the Advancement of Translational Sciences (NCATS) working with Eli Lilly's Research Laboratories branch. NCATS already has a library of more than 3,800 medicines, which will be screened using a Phenotypic Drug Discovery panel owned by Eli Lilly.

The results of the partnership will be available on a public website, and the entire project is scheduled to be completed within 18 months.

Notes NIH: "if an approved medicine is found to be a possible treatment candidate for a new disease indication, a partnership with the organization that owns the chemical compound could be formed to pursue additional studies. These might include clinical trials required for marketing approval by the U.S. Food and Drug Administration."


Read more:

NIH - NIH and Lilly to generate public resource of approved and investigational medicines


Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe